本研究详细介绍了一名 EGFR 基因 19 号外显子缺失的晚期肺腺癌患者。一名 46 岁女性患者被诊断为 IVb 期左肺腺癌，伴有多发骨和淋巴结转移。在鉴定出肿瘤特异性抗原肽后，患者接受了免疫疗法（TSA-DC-CTL）和口服奥希替尼的联合治疗。治疗前后监测外周血循环免疫细胞和循环肿瘤细胞（CTC）。 PET-CT 和 CT 扫描用于评估肿瘤对治疗的反应。观察到患者的总淋巴细胞百分比显着增加，CTC 数量减少。影像学研究显示肿瘤转移显着减少。该报告证明了 TSA-DC-CTL 细胞免疫疗法联合奥希替尼治疗 EGFR 外显子 19 缺失的晚期肺腺癌患者的安全性和有效性。这项研究为患有 EGFR 突变的晚期肺癌患者描述了一种有前景的新治疗选择。© 2024。作者。

This study details a case of a patient with advanced lung adenocarcinoma harboring an exon 19 deletion in the EGFR gene.A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma, with multiple bone and lymph node metastases. Following the identification of tumor-specific antigen peptides, the patient received a combination treatment of immunotherapy (TSA-DC-CTL) and oral osimertinib. Peripheral blood circulating immune cells and circulating tumor cells (CTCs) were monitored before and after treatment. PET-CT and CT scans were used to assess the tumor response to treatment.A significant increase in total lymphocyte percentage and decrease in the number of CTCs in the patient was observed. Imaging studies showed a notable reduction in tumor metastases.This report demonstrates the safety and efficacy of TSA-DC-CTL cell immunotherapy combined with osimertinib in the treatment of a patient with advanced lung adenocarcinoma with an EGFR exon 19 deletions. This study describes a promising new treatment option for patients with advanced lung cancer with EGFR mutations.© 2024. The Author(s).